Boston Strategics begins Phase I trial of anti-cancer agent to treat haematologic malignancies

Boston Strategics (BSC) has started a Phase I clinical trial of Fujifilm's anti-cancer agent FF-10501 in the US to treat patients with advanced haematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news